Consumption and expenditure of drugs used for the treatment of hypercholesterolemia: a governance analysis
The landscape of hypercholesterolemia treatment has expanded with several new therapeutic options. Bempedoic acid may mitigate adverse effects and enhance treatment efficacy, potentially delaying the need for costlier injectable medications like evolocumab, alirocumab, and inclisiran.
Authors
- Angela Panico
- Ferdinando Primiano
- Eduardo Nava (ORCID: https://orcid.org/0000-0003-3259-0511)
- Giuseppe Russo (ORCID: https://orcid.org/0000-0002-7078-1311)
- Francesco Ferrara (ORCID: https://orcid.org/0000-0001-9298-6783)
- Roberto Langella (ORCID: https://orcid.org/0000-0002-9272-8423)
- Ugo Trama (ORCID: https://orcid.org/0000-0001-9473-8943)
- Mariarosa Scognamiglio (ORCID: https://orcid.org/0000-0002-1923-6844)
- Maurizio Capuozzo (ORCID: https://orcid.org/0000-0001-9488-6057)
- Andrea Zovi (ORCID: https://orcid.org/0000-0002-6528-2171)
Institutions
- University of Salerno (IT)
- Giorgio Cini Foundation (IT)
- Regional Health (US)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1080/14737167.2025.2493728
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00